Treatment
Share your love
AAO 2025 Takeaways: Cornea, refractive surgery, and aesthetics redefined | Ophthalmology Times
(Image Credit: AdobeStock/Pixel-Shot) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 delivered major insights into anterior segment innovation, spanning corneal cross-linking care, refractive surgery evolution, and energy-based aesthetic technology. Presentations from Reena Gupta, MD; Arjan…
Clinical Experience and Integration of New Dry Eye Disease Therapies in the Clinic | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Managing Unique Dry Eye Disease Subtypes in Patients | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision | Ophthalmology Times
(Image Credit: AdobeStock/andrew_shots) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 showcased a powerful convergence of innovation in glaucoma care, emphasizing safer long-term pressure control, improved visualization technologies, and more individualized lens decision-making for complex…
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081 | Ophthalmology Times
(Image Credit: AdobeStock/Who is Danny) AAVantgarde and AGC Biologics have entered into an agreement in which AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s dual-vector gene therapies for inherited retinal disorders, AAVB-039 and AAVB-081.1 Most recently, AAVantgarde Bio…
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives | Ophthalmology Times
(Image Credit: AdobeStock/Julien Tromeur) Editor’s Note: This content was generated with the assistance of AI. At AAO 2025, the conversation around retinal disease treatment moved decisively toward the future—one defined by senolytic agents, next-generation gene and optogenetic therapies, disease-modifying approaches…
Ocular Therapeutix randomizes first patient in HELIOS-3 | Ophthalmology Times
(Image Credit: AdobeStock/ronstik) Ocular Therapeutix has randomized the first patient in its HELIOS-3 phase 3 registrational program for AXPAXLI (or OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR). The company describes AXPAXLI as an investigational, bioresorbable, intravitreal hydrogel incorporating…
AAO 2025 Takeaways: How imaging and remote monitoring are transforming retinal care | Ophthalmology Times
(Image Credit: AdobeStock/Mohwet) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 showcased some of the most significant leaps in retinal imaging and disease surveillance the field has seen in over a decade. Three presentations—delivered by…
Orasis Pharmaceuticals introduces starter packs of pilocarpine hydrochloride ophthalmic solution 0.4% | Ophthalmology Times
(Image Credit: AdobeStock/bankoo) Orasis Pharmaceuticals announced the availability of Starter Packs of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% to “broaden access for patients seeking a flexible option to manage their presbyopia and allow greater first-hand experience for eye care professionals.”1…
Clinical and Biologic Distinctions in Managing Retinal Vascular Diseases | Ophthalmology Times
This discussion explores key clinical distinctions that guide treatment decisions across retinal vascular diseases, with a particular focus on differentiating management strategies for branch versus central retinal vein occlusion (BRVO vs. CRVO) and diabetic macular edema (DME). The panel emphasizes…